{
    "Trade/Device Name(s)": [
        "Alere BinaxNOW\u00ae Influenza A & B Card 2",
        "AlereTM Reader"
    ],
    "Submitter Information": "Alere Scarborough, Inc.",
    "510(k) Number": "K162642",
    "Predicate Device Reference 510(k) Number(s)": [
        "K160161"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PSZ"
    ],
    "Summary Letter Date": "February 7, 2017",
    "Summary Letter Received Date": "February 9, 2017",
    "Submission Date": "April 4, 2017",
    "Regulation Number(s)": [
        "21 CFR 866.3328"
    ],
    "Regulation Name(s)": [
        "Influenza virus antigen detection test system"
    ],
    "Analyte Class(es)": [
        "virology",
        "microbiology"
    ],
    "Analyte(s)": [
        "Influenza A nucleoprotein antigen",
        "Influenza B nucleoprotein antigen"
    ],
    "Specimen Type(s)": [
        "Nasopharyngeal swab",
        "Nasal swab"
    ],
    "Specimen Container(s)": [
        "Swab"
    ],
    "Instrument(s)/Platform(s)": [
        "AlereTM Reader"
    ],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay"
    ],
    "Methodologies": [
        "Lateral flow",
        "Qualitative antigen detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Analyzer",
        "Instrument"
    ],
    "Document Summary": "FDA 510(k) summary for Alere BinaxNOW\u00ae Influenza A & B Card 2 rapid immunochromatographic assay and AlereTM Reader for qualitative detection of influenza A and B antigens in nasal and nasopharyngeal swabs",
    "Indications for Use Summary": "Aids in rapid differential diagnosis of influenza A and B infections by qualitative detection of nucleoprotein antigens in nasopharyngeal and nasal swabs; negative results are presumptive and must be confirmed by cell culture or FDA-cleared molecular assay.",
    "fda_folder": "Microbiology"
}